The Developing Countries Interest Group (DCIG) and the Patient and Citizen Involvement Interest Group (PCIG) of HTAi (Health Technology Assessment international; www.htai.org) are currently collaborating in a project with the objective to (1) explore the current routes of patient involvement in Low-and Middle Income Countries (LMICs), (2) collaborate with LMIC stakeholders to define LMIC-specific needs […]
FiercePharma, by Arlene Weintraub, Jan 29, 2019 When Dave Lennon, president of Novartis unit AveXis, said in November that the company’s experimental gene therapy to treat spinal muscular atrophy (SMA) could be cost-effective at a price of $4 million to $5 million, some pricing critics immediately raised red flags. But then the Institute for Clinical […]
NICE, UK, 30 May 2017 NICE is launching an online tool to help medtech companies get their products to patients faster. NICE’s Scientific Advice service is launching an online tool to help developers of medical devices and diagnostics understand and generate the evidence needed to show their products are clinically and cost effective. This will […]
by Nick Paul Taylor on Mar 30, 2017 in FierceBiotech Germany’s healthcare cost watchdog is continuing to push back against the European Medicines Agency’s (EMA) plans to accelerate the approval of new medicines. The German institute worries fast-track drug approvals based on limited clinical trial data or real-world evidence will become the norm—and that this […]
FiercePharma, 22. Apr. 2015 Japan’s health regulators are in the midst of deciding how to conduct cost-effective assessments for drugs and medical devices with under the Central Social Insurance Medical Council, better known as Chuikyo. The Government of Prime Minister Shinzo Abe adopted a plan last year that stipulates the trial rollout of cost-effective assessments […]
Fierce Pharma, February 19, 2015 | By Eric Palmer Drugmakers are often at odds with the National Institute for Health and Care Excellence (NICE) in England, saying it is stingy in what it will approve as payments for their best new treatments. But the industry and the gatekeeper have pulled together in defending against a […]
Fierce Pharma, February 20, 2015 | By Emily Wasserman Bayer has won an approval from England’s National Institute for Health and Care Excellence (NICE) for its popular eye drug Eylea. But it was a mixed result. The drugmaker offered a discount to get the approval and then NICE granted it for some, but not all, […]